Close Menu

NEW YORK (GenomeWeb) – Tianjin Novogene Bioinformatics Technology announced today that the China Food and Drug Administration has approved the firm's NovoFocus NSCLC CDx assay.

The next-generation sequencing-based diagnostic test simultaneously analyzes tumor samples for multiple genomic mutations that are targeted by several CDFA-approved therapies for non-small cell lung cancer, including Iressa (gefitinib), Tagrisso (osimertinib), and Xalkori (crizotinib).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.